Dermatology (Basel, Switzerland) · 2007
Increased number of cytotoxic CD3+ CD28- gammadelta T cells in peripheral blood of patients with cutaneous malignant melanoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Campillo José A, Martínez-Escribano Jorge A, Minguela Alfredo, López-Alvarez Rocío, Marín Luis A, García-Alonso Ana M, Bensussan Armand, Alvarez-López María Rocío
Аннотация
BACKGROUND: A rise of CD3+ TCRgammadelta+ CD28- T cells has previously been observed after an in vitro long-lasting activation or even during viral infection.
OBJECTIVE: The aim of this study was to investigate the expression of CD28 on lymphocytes bearing CD3/TCRgammadelta receptors in cancer, i.e. cutaneous melanoma.
METHODS: TCRgammadelta lymphocytes were analysed in 41 Caucasian melanoma patients and 39 healthy individuals by flow cytometry. Patients were stratified according to the American Joint Committee on Cancer (AJCC) clinical stage.
RESULTS: The number of circulating CD3+ TCRgammadelta+ T cells was significantly increased in both AJCC stages I-II and AJCC stage III patients compared with healthy individuals. This increase was mediated by an accumulation of the CD3+ TCRgammadelta+ CD28- T-cell subset, which expressed a high amount of perforin both in normal individuals and melanoma patients.
CONCLUSION: This work shows, for the first time, a rise of the cytotoxic CD3+ TCRgammadelta+ CD28- T-cell population in melanoma patients, which may be important in anticancer surveillance.
OBJECTIVE: The aim of this study was to investigate the expression of CD28 on lymphocytes bearing CD3/TCRgammadelta receptors in cancer, i.e. cutaneous melanoma.
METHODS: TCRgammadelta lymphocytes were analysed in 41 Caucasian melanoma patients and 39 healthy individuals by flow cytometry. Patients were stratified according to the American Joint Committee on Cancer (AJCC) clinical stage.
RESULTS: The number of circulating CD3+ TCRgammadelta+ T cells was significantly increased in both AJCC stages I-II and AJCC stage III patients compared with healthy individuals. This increase was mediated by an accumulation of the CD3+ TCRgammadelta+ CD28- T-cell subset, which expressed a high amount of perforin both in normal individuals and melanoma patients.
CONCLUSION: This work shows, for the first time, a rise of the cytotoxic CD3+ TCRgammadelta+ CD28- T-cell population in melanoma patients, which may be important in anticancer surveillance.